The impact of Allergic Rhinitis in clinical practice: An International Survey.

Autor:	Passali D; International Federation ORL Societies (IFOS) Executive Board members Rome Italy., Passali GC; UOC di Otorinolaringoiatria, Dipartimento Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della testa collo. Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.; Institute of Otolaryngology, Università Cattolica del Sacro Cuore, Policlinico Agostino Gemelli, Rome, Italy., Damiani V; Medical Deparment, DMG Italy, Pomezia, Italy., Passali FM; Department of Clinical Sciences and Translational Medicine, University of Tor Vergata, Rome, Italy., Cingi C; Department of Otorhinolaryngology, Eskisehir Osmangazi University, Eskisehir, Turkey., Di Girolamo S; 5Department of Clinical Sciences and Translational Medicine, University Tor Vergata, Rome, Italy., Ciprandi G; Consultant allergist, Casa di Cura Villa Montallegro, Genoa, Italy.
Jazyk:	angličtina
Zdroj:	Journal of biological regulators and homeostatic agents [J Biol Regul Homeost Agents] 2021 Jan-Feb; Vol. 35 (1 Suppl. 2), pp. 39-43.
DOI:	10.23812/21-1supp2-8
Abstrakt:	Allergic rhinitis (AR) is a frequent disease caused by an IgE-mediated inflammation of the nose and characterized by typical symptoms. Diagnostic workup is directed to document the production of specific IgE (sensitization). Clinical management aims to relieve symptoms, resolve allergic inflammation, use medications, and potentially induce allergen tolerance, using allergen immunotherapy (AIT). The current survey was conducted in 17 International ear nose throat experts using a questionnaire with 20 questions concerning the practical management of AR patients. It was administered in the 2020 summer. The large majority (94%) of participants use the ARIA classification in clinical practice. On average, subjects with suspected AR represent half of the patients who turn to the ENT experts; 80% have the confirmed diagnosis. Most of the experts use both cutaneous and serum assay to document IgE production. Antihistamines are prescribed in 59% of AR patients, intranasal corticosteroids in 69%, non-adrenergic decongestants in 88%, nasal lavage in 88%, and AIT in 22%. About 68% of AR patients had turbinate hypertrophy, which requires surgery in 62% (mostly surgical decongestion). In conclusion, the current International Survey demonstrated that AR is a common disorder worldwide, the diagnostic workup is mainly based on IgE assessment, and the therapeutic approach is also based on non-pharmacological remedies. (Copyright 2020 Biolife Sas. www.biolifesas.org.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu